MX2020012214A - Composiciones que comprenden moléculas que se unen a la pcsk9 y métodos de uso. - Google Patents

Composiciones que comprenden moléculas que se unen a la pcsk9 y métodos de uso.

Info

Publication number
MX2020012214A
MX2020012214A MX2020012214A MX2020012214A MX2020012214A MX 2020012214 A MX2020012214 A MX 2020012214A MX 2020012214 A MX2020012214 A MX 2020012214A MX 2020012214 A MX2020012214 A MX 2020012214A MX 2020012214 A MX2020012214 A MX 2020012214A
Authority
MX
Mexico
Prior art keywords
pcsk9
compositions
methods
binding molecules
bind
Prior art date
Application number
MX2020012214A
Other languages
English (en)
Inventor
Tracy S Mitchell
Richard Mealey
Original Assignee
Lib Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lib Therapeutics Llc filed Critical Lib Therapeutics Llc
Publication of MX2020012214A publication Critical patent/MX2020012214A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona composiciones farmacéuticas que comprenden proteínas del dominio de andamiaje basado en fibronectina que se unen, por ejemplo, a la proproteína convertasa subtilisina kexina-9 (PCSK9).
MX2020012214A 2018-05-16 2019-05-16 Composiciones que comprenden moléculas que se unen a la pcsk9 y métodos de uso. MX2020012214A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862672187P 2018-05-16 2018-05-16
PCT/US2019/032710 WO2019222529A1 (en) 2018-05-16 2019-05-16 Compositions comprising pcsk9-binding molecules and methods of use

Publications (1)

Publication Number Publication Date
MX2020012214A true MX2020012214A (es) 2021-03-31

Family

ID=68540981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012214A MX2020012214A (es) 2018-05-16 2019-05-16 Composiciones que comprenden moléculas que se unen a la pcsk9 y métodos de uso.

Country Status (12)

Country Link
US (3) US10738102B2 (es)
EP (1) EP3793612A4 (es)
KR (1) KR20210010890A (es)
CN (1) CN112423790A (es)
AU (1) AU2019269617A1 (es)
BR (1) BR112020023344A2 (es)
CA (1) CA3115341A1 (es)
EA (1) EA202092778A1 (es)
MX (1) MX2020012214A (es)
SG (1) SG11202011304QA (es)
WO (1) WO2019222529A1 (es)
ZA (1) ZA202007107B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020023344A2 (pt) * 2018-05-16 2021-02-09 Lib Therapeutics, Llc composições compreendendo moléculas de ligação a pcsk9 e métodos de uso

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009131740A2 (en) * 2008-04-23 2009-10-29 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
KR20130056871A (ko) * 2010-04-13 2013-05-30 브리스톨-마이어스 스큅 컴퍼니 Ｐｃｓｋ９에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
WO2014140210A1 (en) * 2013-03-14 2014-09-18 Pieris Ag Novel binding proteins for pcsk9
IL275497B (en) * 2014-03-20 2022-09-01 Bristol Myers Squibb Co Serum proteins with type iii fibronectin binding domains
JP6644701B2 (ja) * 2014-03-20 2020-02-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 安定化したフィブロネクチンベーススキャフォールド分子
JP6862348B2 (ja) 2015-03-12 2021-04-21 メディミューン，エルエルシー アルブミン融合タンパク質を精製する方法
BR112020023344A2 (pt) * 2018-05-16 2021-02-09 Lib Therapeutics, Llc composições compreendendo moléculas de ligação a pcsk9 e métodos de uso
EP4360642A1 (en) * 2021-06-25 2024-05-01 Gan & Lee Pharmaceuticals Co., Ltd. Pharmaceutical composition of pcsk9 inhibitor and glp-1 receptor agonist

Also Published As

Publication number Publication date
US20200071386A1 (en) 2020-03-05
EA202092778A1 (ru) 2021-05-27
AU2019269617A8 (en) 2020-12-17
EP3793612A4 (en) 2022-03-02
KR20210010890A (ko) 2021-01-28
CA3115341A1 (en) 2019-11-21
AU2019269617A1 (en) 2020-12-03
SG11202011304QA (en) 2020-12-30
US20210002350A1 (en) 2021-01-07
US11692021B2 (en) 2023-07-04
ZA202007107B (en) 2022-03-30
BR112020023344A2 (pt) 2021-02-09
US10738102B2 (en) 2020-08-11
EP3793612A1 (en) 2021-03-24
US20230295270A1 (en) 2023-09-21
JP2021523214A (ja) 2021-09-02
WO2019222529A1 (en) 2019-11-21
CN112423790A (zh) 2021-02-26

Similar Documents

Publication Publication Date Title
MY168961A (en) Antibodies to pcsk9 and uses thereof
ZA201906011B (en) Apoptosis-inducing agents
EA201890949A1 (ru) СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
MX2020002290A (es) Composicion liquida que comprende entidades biologicas y usos de la misma.
EA201791775A1 (ru) Цистеиновая протеаза
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
MY195442A (en) Anti-CD40 Antibodies and Their Uses
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
TN2009000410A1 (en) Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
EA201592304A1 (ru) Способы лечения аутосомно-доминантой гиперхолестеринемии, ассоциированной с мутацией приобретения функции гена pcsk9
BR112015032736A2 (pt) inibidores de bromodomínio cristalino
EA201391329A1 (ru) Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3)
EA201690889A1 (ru) Режимы дозирования для применения ингибиторов pcsk9
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
EP3182971A4 (en) Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity
MY197534A (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
PH12020551716A1 (en) Anti-ror antibody constructs
WO2016172551A8 (en) METHODS OF IDENTIFYING BACTERIA COMPRISING BINDING POLYPEPTIDES
MX2017008908A (es) Proceso para la hidrólisis de queratina empleando proteasas.
JOP20200343A1 (ar) بروتين ربط مولد ضد مضاد لـ steap1
MX2020012214A (es) Composiciones que comprenden moléculas que se unen a la pcsk9 y métodos de uso.
AU2016334102A8 (en) CRMP2 SUMOylation inhibitors and uses thereof
BR112022009587A2 (pt) Anticorpo anti-pcsk9 e uso do mesmo
WO2020102243A3 (en) In-flow photooxygenation of aminothienopyridinones generates novel ptp4a3 phosphatase inhibitors
MX2021002013A (es) Metodos para determinar la concentracion de proteinas o peptidos y sus usos.